Psychedelic therapies are new psychiatric treatments that may need to be combined with existing medications, but little is known about their interactions with common psychiatric drugs. This commentary reviews key findings on such drug-drug interactions and proposes that multimodal neuroimaging, combining PET and fMRI with other measures, offers the most thorough way to study these interactions across molecular, functional, and clinical levels.
This philosophical paper examines the relationship between Alzheimer's disease and consciousness, arguing that the progressive loss of cognitive functions in Alzheimer's does not necessarily entail a loss of subjective experience. The authors contend that even as memory and self-narrative deteriorate, a minimal form of consciousness or 'subjectivity' may persist, challenging purely objective or behavioral assessments of awareness in dementia. They propose that understanding this residual subjectivity requires a phenomenological approach that attends to embodied and affective dimensions of experience, rather than relying solely on neuropsychological metrics. The paper thus advocates for a more nuanced view of personhood and ethical care in Alzheimer's.